Orexin-A and orexin-B are hypothalamic neuropeptides that play critical roles in the maintenance of wakefulness. Intracerebroventricular (ICV) administration of orexin-A has been shown to promote wakefulness and suppress both rapid eye movement (REM) sleep and non-REM (NREM) sleep through the orexin receptor-1 (OX 1 R) and orexin receptor-2 (OX 2 R). Here, we elucidated the differential roles of orexin receptors in the regulation of sleep and wakefulness by comparing the effects of ICV 
INTRODUCTION
Neurons expressing orexins (hypocretins) are distributed within the perifornical lateral hypothalamus and send projections throughout the brain and spinal cord, with particularly dense innervations to nuclei containing monoaminergic and cholinergic neurons constituting the ascending activating system in the brainstem Sakurai et al., 1998; Peyron et al., 1998; Chemelli et al., 1999; Date et al., 1999; Nambu et al., 1999; van den Pol, 1999) . Two subtypes of orexin receptors were also found to be abundantly expressed in these monoaminergic/cholinergic nuclei with distinct distributions (Trivedi et al., 1998; Marcus et al., 2001) . ICV injection of orexin in mice and rats has been shown to increase wakefulness potently and suppress both non-REM (NREM) and REM sleep (Hagan et al., 1999; Piper et al., 2000) , at least partly by acting on these monoaminergic/cholinergic neurons. Loss of orexin neurons is associated with narcolepsy in the human, a condition characterized by excessive daytime sleepiness, sleep-onset REM periods, and cataplexy (sudden bilateral skeletal muscle weakness without impairment of consciousness) Peyron et al., 2000; Thannickal et al., 2000) , highlighting a critical role of orexins in the maintenance of wakefulness.
Mice with targeted deletion of the prepro-orexin gene (orexin -/-mice) display a phenotype strikingly similar to narcolepsy: brief, abrupt behavioral arrests with muscle atonia (i.e., potentially cataplexy), fragmented wakefulness, and direct transitions from wakefulness to REM sleep (Chemelli et al., 1999) . In addition, functionally null mutations in the OX 2 R gene were found in familial narcoleptic dogs (Lin et al., 1999) . Consistently, OX 2 R -/-mice are also narcoleptic, although their phenotype is significantly milder than that of orexin -/-mice (Willie et al., 2003) . In contrast, OX 1 R -/-mice do not exhibit any overt behavioral abnormalities (Sakurai, Mieda et al. -Page 5 5 2007; Hondo et al., 2010) . These observations suggest that the OX 2 R-mediated pathway has a pivotal role, although OX 1 R has an additional role in the regulation of sleep/wake states.
The discovery of a causal link between loss of orexin signaling and narcolepsy has brought about the possibility of novel therapies for the disorder. Indeed, we previously demonstrated that acute ICV administration of orexin-A maintained wakefulness, suppressed sleep, and inhibited cataplectic attacks in a murine model of narcolepsy (Mieda et al., 2004) . Thus, orexin receptor agonists would be of potential value for treating narcolepsy, as well as other conditions of excessive daytime sleepiness in humans. Likewise, dual orexin receptor antagonists, which antagonize both receptors with similar affinity, have been shown to have potential as new medications for the treatment of insomnia (Brisbare-Roch et al., 2007) , although single selective OX 2 R antagonists have been reported to be more effective for sleep promotion than dual antagonists in rats (Dugovic et al., 2009) . Therefore, analysis of the physiological roles of each receptor in sleep/wakefulness regulation is particularly important to understand the mechanisms of the action of these drugs targeted to orexin receptors.
In the present study, we compared the effects of ICV orexin-A administration on sleep/wakefulness states in wild-type mice, OX 1 R -/-mice, and OX 2 R -/-mice. In addition, we histologically determined the subtypes of orexin receptors expressed in neurons implicated in sleep/wakefulness regulation. crosses between homozygous mice) were used (Willie et al., 2003; Sakurai, 2007) . All experimental procedures involving animals were approved by the appropriate institutional animal care and use committees of the University of Texas Southwestern Medical Center at Dallas or Kanazawa University. All efforts were made to minimize animal suffering and discomfort and to reduce the number of animals used.
MATERIALS AND METHODS

Animals
EEG/EMG Recordings Following Intracerebroventricular Administration of
Orexin-A
Mice were anesthetized and implanted with an EEG/EMG implant and a guide cannula as previously described (Mieda et al., 2004) . All animals were allowed to recover for at least 10 days prior to experiments; mice utilized for further study had regained their preoperative body weight and exhibited no obvious sign of infection.
Prior to the sleep/wakefulness evaluation, mice were habituated to the experimental procedure by gentle restraint once a day for two days prior to the experiment.
Each mouse was administered various doses of synthetic orexin-A (0.3, 1, and 3 nmol in 1 µl of sterile artificial cerebrospinal fluid per mouse ICV, Glaxo SmithKline Pharmaceuticals) or vehicle at 3 h into the light phase [zeitgeber time (ZT) 3] using a randomized crossover design at an interval of 3-4 days (Mieda et al., 2004) . Mice were then returned to their home cages for immediate recording of EEG/EMG for the subsequent 8 h. Mice were treated with penicillin-G benzathine / penicillin-G procaine suspension (100,000 U/kg s.c.) after the surgery and each recording session.
Mieda et al. -Page 7
7 EEG/EMG records were visually scored according to standard criteria of rodent sleep and further analyzed using custom software (Chemelli et al., 1999; Willie et al., 2003) . Latencies to NREM sleep and REM sleep were defined as the intervals between the ICV administration and the initiation of the first episodes of NREM sleep and REM sleep, respectively, that continued for at least one epoch (i.e., 20 seconds).
In Situ Hybridization
Preparation of coronal brain sections and single in situ hybridization were performed according to procedures previously described (Mieda et al., 2006 chosen were comparable to those used previously to examine the effects of orexin-A on behavior and metabolism in rodents (Lubkin and Stricker-Krongrad, 1998; Hagan et al., 1999; Piper et al., 2000; Stricker-Krongrad et al., 2002) . The specific action of orexin-A administration on orexin receptors was further confirmed by the lack of any effect when the neuropeptide was administered to
As previously reported, orexin-A administration in wild-type mice increased wakefulness time in a dose-dependent manner (n = 8, p < 0.0001) accompanied by a decrease in NREM sleep time (n = 8, p < 0.0001) (Figs. 1A, 2A, B, D). These effects continued for 2 h after administration at all doses examined (Fig. 1A ).
In OX 1 R -/-mice, the effects of orexin-A administration on wakefulness and NREM sleep were slightly but significantly smaller than those in wild-type mice. The effect of the lowest dose of orexin-A (0.3 nmol) lasted for only 1 h in OX 1 R -/-mice ( Fig. 1B) . During the first 2 h after administration, orexin-A increased wakefulness time (n = 6, p < 0.0001) and suppressed NREM sleep time (n = 6, p < 0.0001) in a dose-dependent manner in OX 1 R -/-mice, but to a degree significantly less than that in wild-type mice (n = 8 and 6 for wild-type and OX 1 R -/-mice, respectively, p = 0.0078 and 0.0082 for wakefulness and NREM sleep, respectively) ( Fig. 2A, B) . However, the latency to the first episode of NREM sleep after administration in OX 1 R -/-mice was not significantly different from that in wild-type mice (n = 8 and 6 for wild-type
and OX 1 R -/-mice, respectively, p = 0.1229) (Fig. 2D ).
In contrast, the effects of orexin-A administration in OX 2 R -/-mice were considerably attenuated as compared to those in both wild-type and OX 1 R -/-mice.
Although all doses of orexin-A examined increased wakefulness in OX 2 R -/-mice in the first hour following administration (n = 6, p = 0.0002 for all three doses as compared to vehicle), these effects dissipated more rapidly when compared with wildtype and OX 1 R -/-mice (Fig. 1C) . Accordingly, the dose response curve of 2 h wakefulness in OX 2 R -/-mice was below those of both wild-type (n = 8 and 6 for wildtype and OX 2 R -/-mice, respectively, p = 0.0001) and OX 1 R -/-mice (n = 6, p = 0.0012), and the dose response curve of 2 h NREM sleep in OX 2 R -/-mice was above those of both wild-type (n = 8 and 6 for wild-type and OX 2 R -/-mice, respectively, p < 0.0001)
and OX 1 R -/-mice (n = 6, p = 0.0011) ( Fig. 2A, B ). In addition, the latency to NREM sleep after orexin-A administration was significantly shorter than that in wild-type (n = 8 and 6 for wild-type and OX 2 R -/-mice, respectively, p < 0.0001) and OX 1 R -/-mice (n = 6, p = 0.0003) (Fig. 2D) . Importantly, although the effect was smaller than observed in the other genotypes, the fact that orexin-A administration increased wakefulness in OX 2 R -/-mice implies that activation of OX 1 R has wakefulnesspromoting effects.
Thus, activation of either of the two orexin receptors was sufficient to increase wakefulness, but to a degree significantly less than that with simultaneous activation of both receptors, suggesting that both OX 1 R and OX 2 R mediate the wakefulnesspromoting and NREM sleep-suppressing effects of ICV orexin-A administration. We also noted that the contributions of OX 2 R to these effects were substantially greater than those of OX 1 R.
Both OX1R and OX2R are similarly involved in orexin-A-mediated REM sleep regulation
As previously reported, orexin-A administration in wild-type mice potently suppressed REM sleep in a dose-dependent manner (n = 8, p < 0.0001) (Figs. 1E, 2C , E). REM sleep suppression lasted for 3 h (3 nmol and 1 nmol orexin-A) or for 2 h (0.3 nmol orexin-A) after administration in wild-type mice (Fig. 1E ). (Trivedi et al., 1998; Marcus et al., 2001) , the tuberomammillary nucleus (TMN) abundantly expressed OX 2 R (Fig. 4A) , and the locus coeruleus (LC) predominantly expressed OX 1 R (Fig. 4B ). In the laterodorsal tegmental nucleus (LDT) and pedunculopontine tegmental nucleus (PPT), many OX 1 R-positive cells and fewer OX 2 R-positive cells with a scattered distribution were observed (Fig. 4D , data not shown). In the dorsal and median raphe nuclei (DR and MnR), OX 1 R and OX 2 R mRNA showed intense labeling with similar spatial patterns (Fig. 4C , data not shown). These distributions of OX 1 R and OX 2 R mRNA were essentially unchanged in mice lacking the other subtype of orexin receptor (Fig. 4A-D However, the expression patterns of orexin receptors in these neurochemicallydefined cells have remained uncertain. Thus, we next performed double in situ hybridization to elucidate histologically the subtype of orexin receptors expressed in these neurons, using vesicular monoamine transporter 2 (VMAT2) and vesicular acetylcholine transporter (VAChT) as molecular markers for monoaminergic and cholinergic neurons, respectively (Erickson et al., 1992; Roghani et al., 1994) . In addition, we also examined co-expression of orexin receptor mRNA and a GABAergic marker glutamic acid decarboxylase 1 (Gad1) mRNA in these monoaminergic and cholinergic nuclei (Huang et al., 1990) , in view of the possible importance of GABAergic interneurons in their functions.
In the TMN (Fig. 5A) In the LC (Fig. 5C ), all VMAT2-positive noradrenergic neurons exhibited intense OX 1 R expression, whereas OX 2 R mRNA was exclusively detected in VMAT2-negative non-noradrenergic neurons. Only some of these OX 2 R-expressing cells exhibited Gad1 expression, leaving the remaining cells neurochemically unidentified (Fig. 6C ).
In the LDT (Fig. 5D ) and PPT (data not shown), all VAChT-positive cholinergic neurons expressed OX 1 R but not OX 2 R mRNA, but many OX 1 R-positive and/or OX 2 R-positive non-cholinergic neurons were intermingled with cholinergic neurons in the area. Gad1 mRNA staining further revealed that OX 1 R-or OX 2 Rexpressing cells included both GABAergic and non-GABAergic cells (Fig. 6D) . A previous study showed that approximately 50% of ChAT immunoreactive neurons in the LDT/PPT also contained GABA (Jia et al., 2003) , and our double in situ hybridization using VAChT and Gad1 probes confirmed at least the existence of such This differential expression of OX 1 R and OX 2 R is summarized in Figure 7 .
DISCUSSION
In the present study, we compared the contribution of OX 1 R and OX 2 R to the effects of ICV orexin-A administration on sleep and wakefulness using mice lacking either OX 1 R or OX 2 R. We administered orexin-A, the dual OX 1 R/OX 2 R agonist, in all mice. Furthermore, we used knockout mice to assure specific and complete deletion of orexin receptor genes. Hence our strategy eliminated confounding factors that could affect results from studies that use subtype-selective orexin agonists and/or antagonists, such as specificity, potency, efficacy, occupancy, and stability of the administered drugs. In addition, the current lack of availability of an OX 1 R-selective agonist supports our strategy. It is possible that the lack of one receptor subtype might be compensated by enhanced expression of the other subtype. However, we found that genetic deletion of OX 1 R or OX 2 R did not result in an overt change in the distribution of the other subtype mRNA (Fig. 4) . However, whether the intensity of expression of the other receptor is altered remains unknown.
In this study, we demonstrated that activation of OX 2 R promotes wakefulness and suppresses NREM sleep with substantially higher efficacy than that of OX 1 R. In contrast, both OX 1 R and OX 2 R appear to be involved in the suppression of REM sleep by orexin-A administration to a similar degree. These findings are consistent with the conclusion derived from behavioral studies and baseline sleep/wakefulness recordings of OX 1 R -/-and OX 2 R -/-mice: the normal regulation of wakefulness/NREM sleep transitions depend critically on OX 2 R, but the profound dysregulation of REM sleep control unique to narcolepsy-cataplexy syndromes emerges from loss of signaling through both OX 1 R and OX 2 R (Willie et al., 2003; Sakurai, 2007) . A previous pharmacological study using OX 1 R-and OX 2 R-selective antagonists in rats also demonstrated a principal role of OX 2 R in suppression of NREM sleep (Dugovic et al., 2009) . Furthermore, ICV administration of an OX 2 R-selective agonist [Ala 11 ]orexin-B in rats was sufficient to promote wakefulness and suppress NREM and REM sleep (Akanmu and Honda, 2005) .
Histaminergic neurons in the TMN are believed to play an important role in the wake-promoting effect of orexin, since the effects of ICV orexin-A administration are markedly attenuated by the histamine H 1 receptor (H 1 R) antagonist pyrilamine, and are absent in H 1 R -/-mice (Huang et al., 2001; Yamanaka et al., 2002) . The TMN abundantly expresses OX 2 R, supporting a critical contribution of TMN histaminergic neurons (Marcus et al., 2001; Yamanaka et al., 2002) . Here, and in agreement with the previous studies, we showed marked attenuation of orexin-A-induced wakefulness in OX 2 R -/-mice. Additionally, we demonstrated expression of OX 2 R mRNA in almost all TMN histaminergic neurons, which is consistent with a previous immunohistochemical study (Yamanaka et al., 2002) . Interestingly, our results suggested co-expression of histaminergic and GABAergic molecular markers with OX 2 R in the TMN, consistent with previous studies showing that TMN histaminergic neurons contain GABA (Ericson et al., 1991; Airaksinen et al., 1992) . Despite dense histaminergic innervation to the ventrolateral preoptic area (VLPO) from TMN, histamine reportedly has no effect on sleep-promoting neurons of this area, which is in notable contrast to the inhibitory effects of noradrenaline, serotonin, and acetylcholine (Gallopin et al., 2000; Chou et al., 2002) . In addition, histidine decarboxylase -/-and H 1 R -/-mice show mild or subtle phenotypes concerning sleep/wakefulness regulation under baseline conditions, clearly contrasting with OX 2 R -/-mice, which show marked abnormalities in sleep and wakefulness (Parmentier et al., 2002; Willie et al., 2003; Huang et al., 2006; Hondo et al., 2010) . Furthermore, OX 1 R -/-;H 1 R -/-mice also show no detectable abnormality in sleep/wakefulness states (Hondo et al., 2010) . Thus, GABAergic transmission by TMN histaminergic neurons, driven by the OX2R (Willie et al., 2003) , may play a critical role, including suppression of sleep-promoting neurons in the VLPO.
However, orexin-A administration in OX 2 R -/-mice still caused an increase in wakefulness. Thus, OX 1 R-expressing neurons may also play a role in the effects of orexin-A. Consistent with this thesis, fragmentation of wakefulness in OX 2 R -/-mice is milder than that in OX 1 R -/-;OX 2 R -/-mice (Sakurai, 2007) . In addition, ICV administration of an OX 2 R-selective agonist [Ala 11 ]orexin-B seemed less effective when compared with orexin-A (Akanmu and Honda, 2005) . However, ICV administration of orexin-A in OX 2 R-deficient dogs has been reported to have no effect on time spent in wakefulness (Fujiki et al., 2003) . This discrepancy between the studies with OX 2 R-defficient mice and dogs may be explained by differences in doses, time windows of analyses, numbers of animals examined, and species (Willie et al., 2003) .
LC noradrenergic neurons, which abundantly express OX 1 R, are one of the candidate systems to mediate the arousal effect mediated by OX 1 R. Indeed, microinjection of orexin-A into the LC increases wakefulness (Bourgin et al., 2000) .
Other regions that could mediate OX 1 R-induced arousal effects include cholinergic neurons in the LDT/PPT, and serotonergic neurons in the raphe nuclei, both of which are thought to be critically involved in the regulation of sleep/wakefulness states (Pace-Schott and Hobson, 2002; Sakurai, 2007) . Redundant expression of both OX 1 R and OX 2 R mRNA was reported in raphe nuclei (Marcus et al., 2001) . We showed that most serotonergic neurons in the DR and MnR are positive for OX 1 R and/or OX 2 R mRNA, which is in accordance with a previous single-cell PCR study (Brown et al., 2001 ). In addition to the direct excitatory effects, orexins act indirectly to activate local inhibitory GABAergic input to serotonergic neurons . This is consistent with our present finding of expression of orexin receptors in GABAergic neurons of the DR/MnR. (Lee et al., 2005; Mileykovskiy et al., 2005; Takahashi et al., 2008) . It is possible that extremely low activity of orexin neurons or residual orexin neuropeptides in the extracellular fluid during NREM sleep after wakefulness may prevent the induction of REM sleep.
Previous findings also suggest gating of NREM/REM sleep transitions by orexin-A. First, local administration of orexin-A into the LC of rats, which abundantly expresses OX 1 R, suppressed REM sleep without significant alteration in NREM sleep (Bourgin et al., 2000) . Second, systemic administration of a selective OX 1 R antagonist SB-334867 reversed REM sleep suppression caused by ICV orexin-A administration at a dose which produced no significant change in NREM sleep (Smith et al., 2003) . In addition, deficiency in this type of REM sleep regulation may underlie the unproportionally large increase in REM sleep time when compared with the increase in NREM sleep in narcoleptic orexin -/-and OX 1 R -/-;OX 2 R -/-mice (Chemelli et al., 1999; Sakurai, 2007) . These observations suggest that orexin-A-mediated suppression of REM sleep might primarily be mediated by noradrenergic neurons in the LC, which send collateral projections to cholinergic neurons in the LDT/PPT.
Differential expression of orexin receptors in cholinergic and GABAergic neurons of the LDT/PPT is also intriguing. Exclusive expression of OX 1 R in cholinergic neurons is also supported by a previous study demonstrating that the excitatory effects of orexin-A on PPT cholinergic neurons were suppressed by a selective OX 1 R antagonist SB-334867 (Kim et al., 2009) . Cholinergic neurons in these areas include those that are active during wakefulness and REM sleep (W/REMon neurons) and those that are specifically active during REM sleep (REM-on neurons) (Pace-Schott and Hobson, 2002; Sakurai, 2007) . The latter population is likely to play a critical role in REM sleep-related physiological phenomena, including muscle atonia. Nevertheless, orexin-A excites both cholinergic and non-cholinergic neurons of the LDT in slice preparations (Burlet et al., 2002) . Furthermore, orexin-A microinjection in the cat LDT increases wakefulness and reduces REM sleep (Xi et al., 2001) . A recent study suggested that GABAergic neurons in the PPT mediate suppression of REM sleep and muscle atonia following local injection of orexin-A into this area . Taken together, these results indicate that in the LDT/PPT, orexin may activate W/REM-on cholinergic neurons through OX 1 R to facilitate wakefulness. Simultaneously, orexin might activate GABAergic interneurons to inhibit REM-on cholinergic neurons in these nuclei. Additionally, orexinergic activation of wake-active noradrenergic and serotonergic neurons in the LC and raphe nuclei is likely to counteract activation of REM-on cholinergic neurons in the LDT/PPT during wakefulness (Pace-Schott and Hobson, 2002; Sakurai, 2007) . This is consistent with the fact that tricyclic antidepressants and serotonin-specific reuptake inhibitors are effective for treating cataplexy in narcoleptic patients.
In conclusion, our findings highlight the complex redundant and/or compensatory pathways involving OX 1 R and OX 2 R mediating the effects of orexin-A administration on sleep/wakefulness regulation (Fig. 7) . Thus, dual agonists for both OX 1 R and OX 2 R might have greater potential than subtype-selective agonists as novel treatments for narcolepsy and other states of hypersomnolence. 
